<DOC>
	<DOCNO>NCT01838876</DOCNO>
	<brief_summary>The objective study evaluate long-term safety tolerability cariprazine adjunctive treatment antidepressant therapy ( ADT ) patient Major Depressive Disorder ( MDD ) .</brief_summary>
	<brief_title>To Evaluate Long-term Safety Tolerability Cariprazine Adjunctive Treatment Antidepressant Therapy ( ADT ) Patients With Major Depressive Disorder ( MDD )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<criteria>Patients provide consent prior study specific procedure Meet DSMIVTR criterion MDD New patient must ongoing inadequate response protocol allow ADTs report Antidepressant Treatment Response Questionnaire ( ATRQ ) For rollover patient RGHMD72 , completion Study RGHMD72 ( either doubleblind singleblind treatment period ) continue ADT treatment . Patients meet DSMIVTR criterion MDD</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>MDD</keyword>
	<keyword>Depression</keyword>
</DOC>